JP2019506842A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019506842A5 JP2019506842A5 JP2018528604A JP2018528604A JP2019506842A5 JP 2019506842 A5 JP2019506842 A5 JP 2019506842A5 JP 2018528604 A JP2018528604 A JP 2018528604A JP 2018528604 A JP2018528604 A JP 2018528604A JP 2019506842 A5 JP2019506842 A5 JP 2019506842A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- amino acid
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 414
- 239000000427 antigen Substances 0.000 claims description 147
- 102000036639 antigens Human genes 0.000 claims description 147
- 108091007433 antigens Proteins 0.000 claims description 147
- 239000012634 fragment Substances 0.000 claims description 119
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- 201000011510 cancer Diseases 0.000 claims description 27
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims description 21
- 101710120217 Fc receptor-like protein 5 Proteins 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 16
- 210000004027 cell Anatomy 0.000 claims description 15
- 208000034578 Multiple myelomas Diseases 0.000 claims description 14
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 229940127121 immunoconjugate Drugs 0.000 claims description 11
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 7
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 4
- 101710112752 Cytotoxin Proteins 0.000 claims description 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 3
- 239000002619 cytotoxin Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 210000002865 immune cell Anatomy 0.000 claims description 2
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 318
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 6
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 3
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 3
- 208000017604 Hodgkin disease Diseases 0.000 claims 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 3
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 201000009277 hairy cell leukemia Diseases 0.000 claims 3
- 201000000564 macroglobulinemia Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001093 anti-cancer Effects 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 description 160
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 24
- 238000012986 modification Methods 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022000137A JP2022033256A (ja) | 2015-12-04 | 2022-01-04 | Ｆｃ受容体様５を標的とする抗体および使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562263586P | 2015-12-04 | 2015-12-04 | |
| US62/263,586 | 2015-12-04 | ||
| PCT/US2016/064550 WO2017096120A1 (en) | 2015-12-04 | 2016-12-02 | Antibodies targeting fc receptor-like 5 and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022000137A Division JP2022033256A (ja) | 2015-12-04 | 2022-01-04 | Ｆｃ受容体様５を標的とする抗体および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019506842A JP2019506842A (ja) | 2019-03-14 |
| JP2019506842A5 true JP2019506842A5 (https=) | 2020-01-16 |
| JP7267009B2 JP7267009B2 (ja) | 2023-05-01 |
Family
ID=58797867
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018528604A Active JP7267009B2 (ja) | 2015-12-04 | 2016-12-02 | Ｆｃ受容体様５を標的とする抗体および使用方法 |
| JP2022000137A Pending JP2022033256A (ja) | 2015-12-04 | 2022-01-04 | Ｆｃ受容体様５を標的とする抗体および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022000137A Pending JP2022033256A (ja) | 2015-12-04 | 2022-01-04 | Ｆｃ受容体様５を標的とする抗体および使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10913796B2 (https=) |
| EP (1) | EP3383913A4 (https=) |
| JP (2) | JP7267009B2 (https=) |
| KR (1) | KR20180089497A (https=) |
| CN (2) | CN109071654B (https=) |
| AU (2) | AU2016362402A1 (https=) |
| BR (1) | BR112018011336A2 (https=) |
| CA (1) | CA3007115A1 (https=) |
| IL (2) | IL259747B (https=) |
| MX (1) | MX2018006787A (https=) |
| MY (1) | MY197441A (https=) |
| NZ (1) | NZ743124A (https=) |
| PH (1) | PH12018501177B1 (https=) |
| SA (1) | SA518391722B1 (https=) |
| SG (2) | SG11201804656PA (https=) |
| WO (1) | WO2017096120A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015357543B2 (en) * | 2014-12-05 | 2021-10-21 | Eureka Therapeutics, Inc. | Chimeric antigen receptors targeting Fc Receptor-like 5 and uses thereof |
| CN118271463A (zh) | 2014-12-05 | 2024-07-02 | 纪念斯隆-凯特琳癌症中心 | 靶向g-蛋白偶联受体的嵌合抗原受体及其用途 |
| KR20180019725A (ko) * | 2015-06-23 | 2018-02-26 | 메모리얼 슬로안-케터링 캔서 센터 | 신규의 피디 1 면역 조절제 |
| MX2018004721A (es) | 2015-10-23 | 2018-07-06 | Eureka Therapeutics Inc | Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas. |
| BR112018011336A2 (pt) | 2015-12-04 | 2018-12-04 | Memorial Sloan-Kettering Cancer Center | anticorpo anti-fcrl5 isolado ou um fragmento de ligação ao antígeno do mesmo, anticorpo scfv anti-fcrl5 isolado, anticorpo isolado ou porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico isolado, vetor de expressão, célula hospedeira, método para detectar fcrl5 em uma célula ou tecido inteiro, método para tratar câncer em um indivíduo, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo, kit para tratar câncer |
| JP7538601B2 (ja) | 2017-04-26 | 2024-08-22 | ユーリカ セラピューティックス， インコーポレイテッド | キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用 |
| US20200371091A1 (en) | 2017-11-30 | 2020-11-26 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
| AU2018394939B2 (en) | 2017-12-29 | 2022-02-24 | Ap Biosciences, Inc. | Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy |
| KR102870868B1 (ko) | 2018-06-01 | 2025-10-15 | 노파르티스 아게 | Bcma에 대한 결합 분자 및 이의 용도 |
| JP6761889B1 (ja) * | 2019-11-11 | 2020-09-30 | 株式会社Ｇｓｐエンタープライズ | 抗ヒトＣｒｉｐｔｏ−１抗体 |
| TWI789711B (zh) * | 2020-02-24 | 2023-01-11 | 中國科學院微生物研究所 | 新型冠狀病毒的人源單克隆抗體及其應用 |
| EP4240756A1 (en) | 2020-11-04 | 2023-09-13 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
| CA3199095A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
| WO2022150809A1 (en) * | 2021-01-05 | 2022-07-14 | Immunome, Inc. | Antibody cocktail against sars-cov-2 spike protein |
| CN117693508A (zh) | 2021-03-03 | 2024-03-12 | 朱诺治疗学股份有限公司 | T细胞疗法和dgk抑制剂的组合 |
| JP2024517863A (ja) | 2021-05-06 | 2024-04-23 | ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 細胞を刺激し、形質導入する方法 |
| JP2024523316A (ja) * | 2021-06-18 | 2024-06-28 | オートラス リミテッド | Ｃａｒ ｔ細胞における、および疾患の処置のための抗ｃｄ３０７ｅ単一ドメイン抗体、その使用 |
| US20250297282A1 (en) | 2022-05-05 | 2025-09-25 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| JP2025525439A (ja) | 2022-06-30 | 2025-08-05 | インダプタ セラピューティクス インコーポレイテッド | 操作されたナチュラルキラー（ｎｋ）細胞と抗体療法との組み合わせおよび関連する方法 |
| WO2024047558A2 (en) * | 2022-08-31 | 2024-03-07 | Immuneel Therapeutics Private Limited | Antigen-binding proteins and chimeric antigen receptors specific for domain 9 of human cd307e |
| EP4583876A1 (en) | 2022-09-08 | 2025-07-16 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
| WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
| WO2024102948A1 (en) * | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
| JP2026504491A (ja) | 2023-02-03 | 2026-02-05 | ツェー３エス２ ゲーエムベーハー | 操作された免疫細胞の非ウイルス的製造のための方法 |
| WO2024218650A1 (en) * | 2023-04-19 | 2024-10-24 | Pfizer Inc. | Lilrb1 and lilrb2 antibodies and methods of use thereof |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| US20250144234A1 (en) | 2023-11-02 | 2025-05-08 | Capstan Therapeutics Inc. | RNA for In vivo Transfection with Increased Expression |
| US20250332281A2 (en) | 2023-12-15 | 2025-10-30 | Capstan Therapeutics, Inc. | Humanized anti-cd8 antibodies and uses thereof |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2026025092A1 (en) | 2024-07-26 | 2026-01-29 | Juno Therapeutics, Inc. | Synthetic promoters for t cell expression |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| CZ294359B6 (cs) | 1993-09-03 | 2004-12-15 | Chugai Seiyaku Kabushiki Kaisha | Monoklonální protilátka způsobující apoptózu buněk kostní dřeně, její fragment, hybridom ji produkující a farmaceutický prostředek, který ji obsahuje |
| SI1232392T1 (en) * | 1999-10-12 | 2003-10-31 | Connex Gesellschaft Zur Optimierung Von Forschung Und | Improved method for the detection of acid resistant bacteria of the genus helicobacter in stool |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| PT2281843T (pt) * | 2000-06-16 | 2017-01-02 | Human Genome Sciences Inc | Anticorpos que se ligam imunoespecificamente a blys |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| AU2003216341A1 (en) * | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| WO2006039238A2 (en) | 2004-09-30 | 2006-04-13 | The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Irta2 antibodies and methods of use |
| KR20070115881A (ko) | 2005-01-12 | 2007-12-06 | 메다렉스, 인코포레이티드 | 아이아르티에이-2 항체 및 그의 용도 |
| CN101233156B (zh) * | 2005-06-20 | 2012-06-27 | 米德列斯公司 | Cd19抗体及其用途 |
| SI2856876T1 (en) | 2007-03-30 | 2018-04-30 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| EP2065398A1 (en) * | 2007-11-29 | 2009-06-03 | Cytos Biotechnology AG | Human monoclonal nicotine specific antibodies |
| EP2650017A3 (en) * | 2008-02-05 | 2014-01-22 | Bristol-Myers Squibb Company | Alpha 5 - beta 1 antibodies and their uses |
| RU2583270C2 (ru) | 2009-04-01 | 2016-05-10 | Дженентек, Инк. | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| RU2587621C2 (ru) | 2009-04-01 | 2016-06-20 | Дженентек, Инк. | АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| TR201904484T4 (tr) | 2009-11-03 | 2019-05-21 | Hope City | Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt). |
| WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| CN113684185A (zh) | 2013-02-26 | 2021-11-23 | 纪念斯隆-凯特琳癌症中心 | 用于免疫疗法的组合物和方法 |
| WO2014191128A1 (en) | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| TWI725931B (zh) | 2013-06-24 | 2021-05-01 | 美商建南德克公司 | 抗ｆｃｒｈ５抗體 |
| US20170335281A1 (en) | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| AU2015357543B2 (en) * | 2014-12-05 | 2021-10-21 | Eureka Therapeutics, Inc. | Chimeric antigen receptors targeting Fc Receptor-like 5 and uses thereof |
| BR112018011336A2 (pt) | 2015-12-04 | 2018-12-04 | Memorial Sloan-Kettering Cancer Center | anticorpo anti-fcrl5 isolado ou um fragmento de ligação ao antígeno do mesmo, anticorpo scfv anti-fcrl5 isolado, anticorpo isolado ou porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico isolado, vetor de expressão, célula hospedeira, método para detectar fcrl5 em uma célula ou tecido inteiro, método para tratar câncer em um indivíduo, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo, kit para tratar câncer |
-
2016
- 2016-12-02 BR BR112018011336-0A patent/BR112018011336A2/pt not_active IP Right Cessation
- 2016-12-02 IL IL259747A patent/IL259747B/en unknown
- 2016-12-02 EP EP16871553.0A patent/EP3383913A4/en active Pending
- 2016-12-02 SG SG11201804656PA patent/SG11201804656PA/en unknown
- 2016-12-02 SG SG10202005268WA patent/SG10202005268WA/en unknown
- 2016-12-02 MX MX2018006787A patent/MX2018006787A/es unknown
- 2016-12-02 JP JP2018528604A patent/JP7267009B2/ja active Active
- 2016-12-02 PH PH1/2018/501177A patent/PH12018501177B1/en unknown
- 2016-12-02 CN CN201680081027.5A patent/CN109071654B/zh active Active
- 2016-12-02 IL IL295295A patent/IL295295A/en unknown
- 2016-12-02 AU AU2016362402A patent/AU2016362402A1/en not_active Abandoned
- 2016-12-02 CN CN202211132436.7A patent/CN116063508A/zh active Pending
- 2016-12-02 NZ NZ743124A patent/NZ743124A/en not_active IP Right Cessation
- 2016-12-02 MY MYPI2018000851A patent/MY197441A/en unknown
- 2016-12-02 CA CA3007115A patent/CA3007115A1/en active Pending
- 2016-12-02 WO PCT/US2016/064550 patent/WO2017096120A1/en not_active Ceased
- 2016-12-02 KR KR1020187019114A patent/KR20180089497A/ko not_active Withdrawn
-
2018
- 2018-06-03 SA SA518391722A patent/SA518391722B1/ar unknown
- 2018-06-04 US US15/997,155 patent/US10913796B2/en active Active
-
2021
- 2021-01-07 US US17/143,833 patent/US20210388081A1/en active Pending
-
2022
- 2022-01-04 JP JP2022000137A patent/JP2022033256A/ja active Pending
-
2023
- 2023-12-14 AU AU2023282276A patent/AU2023282276A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019506842A5 (https=) | ||
| TWI821474B (zh) | Ｃｄ３抗體及其藥物用途 | |
| JP2021524267A5 (https=) | ||
| CN112969476B (zh) | 多特异性蛋白分子 | |
| KR20180089497A (ko) | Fc 수용체-유사 5를 표적화하는 항체 및 사용 방법 | |
| US9725519B2 (en) | Antibody against transporter and use thereof | |
| JP2017523786A5 (https=) | ||
| JP2017530722A5 (https=) | ||
| JP2018500014A5 (https=) | ||
| WO2020257760A1 (en) | Anti-tigit antibodies | |
| CN114014930A (zh) | 结合ctla4的抗体治疗剂 | |
| JP2024501894A5 (https=) | ||
| WO2020238926A1 (en) | Anti-b7-h3 antibodies | |
| JP2012513214A5 (https=) | ||
| JP2021524275A5 (https=) | ||
| JP2011207882A5 (https=) | ||
| CN113583116A (zh) | 针对SARS-CoV-1或SARS-CoV-2的抗体及其用途 | |
| CN115397857B (zh) | 一种抗pd-l1和pd-l2抗体及其衍生物和用途 | |
| JP2018514193A5 (https=) | ||
| CN113631582A (zh) | 一种融合蛋白及其用途 | |
| CN1329413C (zh) | 一种治疗或预防老年性痴呆的抗体及其表达载体和在制药中的应用 | |
| WO2021254574A2 (en) | Cd38 antibodies for the treatment of human diseases | |
| JP2025506248A5 (https=) | ||
| JPWO2022114163A5 (https=) | ||
| CN116284407A (zh) | 一种抗gucy2c抗体或其抗原结合片段及其用途 |